Tatva Chintan Pharma Chem Limited — Q1 FY27 earnings call

Call held 17 Jul 2026

Management summary

Tatva Chintan Pharma Chem Limited reported robust Q1 FY27 results with significant YoY growth in revenue and EBITDA, driven by strong performance in PTC, PASC, and SDA segments. A key highlight was the successful qualification of its first commercial-scale semiconductor product and the approval of a new INR 200 crore greenfield facility. While the Electrolyte Salts segment faced headwinds from raw material shortages, management expressed confidence in maintaining a 20-25% compounded annual growth rate over the next 3-4 years and an EBITDA margin of 20-22%.

Highlights

  • Operating revenue of INR 167.1 crores, up 43% YoY and 25% QoQ.

  • EBITDA of INR 32.3 crores, up 86% YoY and 15% QoQ.

  • First commercial-scale semiconductor product batch successfully qualified by customer, marking a significant achievement.

  • New greenfield manufacturing facility approved with INR 200 crores investment to support future growth and new products.

  • Pharma & Agro Intermediates and Specialty Chemicals (PASC) revenue grew 63% QoQ and 25% YoY to INR 58.4 crores.

Concerns

  • Electrolyte Salts revenue declined 52% QoQ to INR 6.3 crores due to severe short supply of key raw materials from Middle East crisis.

  • Glymes business impacted by aggressive pricing from Chinese suppliers, leading to a decision to withhold further capacity investment.

  • Major commercialization for semiconductor products is not expected before Q4 2028 due to rigorous validation processes.

Key financials

  1. Operating Revenue ₹167.1 Cr +43%YoY
  2. EBITDA ₹32.3 Cr +86%YoY

What they filed

Q1 FY27: revenue up 42.7%, net profit up 128.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue83 86 108 117 124 +49%131 +52%134 +24%167 +43%
EBITDA6 7 9 17 22 +267%25 +257%28 +211%32 +88%
Net profit-1 0 1 7 10 +1100%15 10 +900%16 +129%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹165.3 Cr Total
  • Pharma & Agro Intermediates and Specialty Chemicals (PASC) ₹58.4 Cr 35.3%
  • Structure Directing Agents (SDA) ₹57.8 Cr 35.0%
  • Phase Transfer Catalysts (PTC) ₹42.8 Cr 25.9%
  • Electrolyte Salts ₹6.3 Cr 3.8%

Capital allocation

high confidence
  • Capex ₹200 Cr
    • New greenfield manufacturing facility for commercialization of new products, greater operational flexibility, and capacity for next phase of growth. ₹200 Cr
    In line with the growing opportunities across our business, I'm pleased to share that our Board of Directors has today approved the establishment of a new greenfield manufacturing facility involving an investment of approximately INR200 crores.

Guidance & targets

Revenue

  • Compounded Annual Revenue Growth Rate Revenue · next 3-4 years · Medium confidence 20-25%
    So over the next 3 to 4 years, if you let us pick because Jolva was getting commercialized. So let us say about coming 4 years from today, we should envisage at least 20% to 25% compounded growth year-on-year basis.

    — Chintan Shah

  • Electrolyte Salts Revenue Contribution Revenue · FY27 · High confidence INR 40-60 crores
    It will not be up to so between INR40 crores to INR60 crores revenue is what we still hold the guidance.

    — Chintan Shah

  • New Pharma Molecules Incremental Revenue Revenue · current financial year · High confidence INR 70-80 crores
    It should contribute around INR70 crores to INR80 crores of revenue from all these pharma molecules. And in this current financial year.

    — Ajesh Pillai

  • New Pharma Molecules Revenue at Full Utilization Revenue · full utilization · High confidence INR 200 crores
    INR200 crores. In the range of INR200 crores.

    — Ajesh Pillai

  • Q1 FY27 Revenue Run Rate Maintenance Revenue · full year · High confidence 25-30% growth
    We see, yes, so 25%, 30% growth is what we forecasted, and that's what we stick to. So yes, in pure mathematics terms, we are saying that, yes, we should maintain this run rate.

    — Chintan Shah

Capex

  • Revenue from new greenfield facility at peak utilization Capex · at peak utilization · Medium confidence INR 300 crores
    And as far as the revenue is concerned, we would be looking at somewhere around 1.2x to 1.5x asset turnover ratio, which means we would end up having around INR300 crores of revenue at peak utilization.

    — Raman K.V.

Profitability

  • EBITDA Margin Profitability · full year · High confidence 20-22%
    As I always say, so unfortunately, we have lost 1 quarter with a little lesser margin, but I would still stick to 20%, 22% margins in guidance.

    — Chintan Shah

Commercialization

  • Semiconductor Major Commercialization Commercialization · Q4 2028 · High confidence Not before Q4 2028
    Because we don't honestly speaking, we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028.

    — Chintan Shah

Capacity

  • Greenfield Facility Operational Timeline Capacity · within 21 months · High confidence within 18-21 months
    So theoretically, we want to finish it. So theoretically, we say we want this site to be in place within -- into operations within 21 months. Internally, we are pushing to get it through within 18 months, if possible.

    — Chintan Shah

What to watch in Q2 FY27

Greenfield Facility Construction Progress

next quarter
Current Groundbreaking ceremony on 20th July 2026
Target Progress towards 18-21 month completion timeline

Why it matters

Tracking the execution of this significant capex project is crucial for future capacity and revenue growth.

We have scheduled the groundbreaking ceremony for this on 20th July 2026. This investment reflects our confidence in the future rather than merely addressing today's requirements.

Risks & concerns

  • Raw material supply chain disruptions

    medium

    Severe short supply of key raw materials due to Middle East crisis led to significant production delays for Electrolyte Salts, impacting Q1 revenue recognition.

    Management acknowledged

  • Chinese competition and aggressive pricing

    medium

    Aggressive pricing from Chinese suppliers (price drop from $4.6-4.8 to $2.1) impacted the Glymes business, leading to a decision to withhold further capacity investment.

    Management acknowledged

  • Long validation cycles for new products, especially semiconductors

    medium

    Semiconductor products require rigorous validation processes, with major commercialization not expected before Q4 2028, requiring patience and sustained investment.

    Management acknowledged

  • Geopolitical developments and evolving trade dynamics

    low

    Potential removal of VAT/subsidies in China from January next year could impact the competitive landscape, though it might also benefit Tatva Chintan.

    Management acknowledged

Q&A highlights

6 direct
Glymes for Lithium-ion Batteries and Business Strategy Direct
So basically, MONOGLYME is one of the key products which we are doing on conventional chemistry and converting it into the continuous flow chemistry. By the time we actually successfully translated this into continuous flow chemistry to make it more sustainable, the environment scenario in terms of pricing has become too aggressive from the Chinese supplies. So, we have withheld our plan to invest as of now into the glyme's capacity addition.

Clarified that Glymes are primarily for the pharma industry, not lithium-ion batteries, and explained the decision to halt capacity expansion due to aggressive Chinese pricing, indicating market challenges and strategic adaptation.

Asked by Shlok Patel

Semiconductor Product Details, Value Chain Position, and Addressable Market Partial
Basically, the application of this product, what we have now commercialized, the first commercial supply that became successful. So this product has application getting into as a key starting raw materials to make the semiconductor. So it's a key starting block to make the semiconductor. Parallelly, it also has applications in etching of the printed circuit boards, as well as in cleaning of the circuits.

Provided detailed insight into the specific applications of their semiconductor product (key starting material, etching, cleaning agent) and clarified that they supply to MNCs who then supply fabs, not directly to fabs. Also highlighted the early stage of market assessment.

Asked by Raman K.V.

Purpose and Revenue Potential of New Greenfield Capex Direct
So, this facility is more going to take care of these requirements. And as far as the revenue is concerned, we would be looking at somewhere around 1.2x to 1.5x asset turnover ratio, which means we would end up having around INR300 crores of revenue at peak utilization.

Explained that the INR 200 crore greenfield capex is for R&D-ready products and domestic demand, projecting a significant INR 300 crores revenue at peak utilization, indicating a clear growth strategy tied to new capacity.

Asked by Raman K.V.

Electrolyte Salts FY27 Guidance and Raw Material Challenges Direct
It will not be up to so between INR40 crores to INR60 crores revenue is what we still hold the guidance. And yes, we have enough capacities in place to cater to this demand. So we don't have to do anything special to achieve this revenue. Now everything is in place. Customer demands are very crystal clear, very highly visible. So, it's just moving about in this zone.

Reiterated confidence in the INR 40-60 crore revenue guidance for Electrolyte Salts despite Q1's sequential decline, attributing past issues to raw material unavailability due to geopolitical events, and signaling a recovery.

Asked by Raman K.V.

Impact of China's Anti-Involution Policies on Chemical Industry Partial
This is still news, but it's not a law. So, this, if at all happens, is expected to be in place from January of next year. So, this is what we keep hearing from customers and suppliers both. But let us see as and when it happens. So, most of the subsidies in terms of specialty chemicals or agro intermediates or pharma intermediates is expected to go away.

Addressed the potential impact of China removing VAT/subsidies, suggesting it could benefit Tatva Chintan by leveling the playing field, but cautioned that it's too early to predict the full implications.

Asked by Gourab Paul

Semiconductor Commercialization Timeline and Capex Plans Direct
Not at the moment. Because we don't honestly speaking, we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028. I don't see that it will commercialize in a large volume because it's going to take its own sweet time.

Provided a clear, long-term timeline for major semiconductor commercialization (not before Q4 2028) and confirmed no immediate capex plans for this segment, managing investor expectations regarding its near-term revenue contribution.

Asked by Nirali Gopani

Benefits and Strategic Focus on Continuous Flow Chemistry Direct
On all the fronts, you see improvements happening in terms of your productivity going up, in terms of your cost coming down, in terms of certain -- basically, certain base chemistries, you are able to reduce the number of stages of chemistry. For example, the 2-stage product, you can do it in a one single stage.

Highlighted the strategic importance of continuous flow chemistry, detailing its benefits in improving productivity, reducing costs, and optimizing chemical processes, indicating a key technological focus for future products and existing product conversion.

Asked by Rohit

Full-Year EBITDA Margin Guidance Direct
As I always say, so unfortunately, we have lost 1 quarter with a little lesser margin, but I would still stick to 20%, 22% margins in guidance.

Reaffirmed the full-year EBITDA margin guidance of 20-22%, providing clarity on profitability expectations despite a slightly lower margin in the reported quarter.

Asked by Nirali Gopani

3 min read 6 chapters

Detailed narrative

Strong Q1 FY27 Financial Performance

Tatva Chintan Pharma Chem Limited reported robust financial results for Q1 FY27, with operating revenue reaching INR 167.1 crores, marking a 43% year-on-year growth and a 25% sequential increase. EBITDA stood at INR 32.3 crores, reflecting an 86% growth year-on-year and a 15% improvement over the previous quarter. This performance indicates a strong start to the financial year, driven by broad-based growth across most business segments.

Strategic Investment in Greenfield Manufacturing Facility

The company's Board of Directors approved a significant investment of approximately INR 200 crores for a new greenfield manufacturing facility, with groundbreaking scheduled for July 20, 2026. This multi-purpose facility is designed to be future-ready, supporting the commercialization of new products, enhancing operational flexibility, and providing the necessary capacity for the company's next phase of growth. Management expects this facility to generate around INR 300 crores in revenue at peak utilization, based on a 1.2x to 1.5x asset turnover ratio, and aims for operational readiness within 18-21 months.

Breakthrough in Semiconductor Business

Tatva Chintan achieved a significant milestone by successfully delivering and qualifying its first commercial-scale batch of a semiconductor product. This product serves as a key starting raw material for semiconductors, as well as an etching and cleaning agent. While the addressable market is still being gauged and major commercialization is not anticipated before Q4 2028 due to rigorous validation processes, this achievement validates the company's research capabilities and ability to meet demanding industry standards, opening doors for larger opportunities.

Mixed Performance and Outlook for Key Segments

The Phase Transfer Catalysts (PTC) and Structure Directing Agents (SDA) segments demonstrated strong growth, with revenues of INR 42.8 crores (up 47% YoY) and INR 57.8 crores (up 47% YoY), respectively. The Pharma & Agro Intermediates and Specialty Chemicals (PASC) segment also performed well, growing 63% QoQ and 25% YoY to INR 58.4 crores, with commercial production of a pharma intermediate commencing in Q1. However, the Electrolyte Salts segment saw a 52% sequential decline to INR 6.3 crores due to raw material supply disruptions caused by the Middle East crisis, though management expects recovery towards its INR 40-60 crores FY27 guidance.

Focus on Continuous Flow Chemistry and Product Pipeline

The company is strategically focusing on continuous flow chemistry, with two commercial molecules currently utilizing this technology and 7-8 more products in the pipeline expected to transition to commercial or piloting phases using electrochemistry or continuous flow. This shift aims to improve productivity, reduce costs, and optimize chemical processes, thereby releasing reactor capacity. Excluding semiconductor products, Tatva Chintan has about 9 different mature products in its pipeline, with 5 semiconductor products also under various stages of development.

Guidance Reiteration and Market Dynamics

Management reiterated its full-year EBITDA margin guidance of 20-22% and expects to maintain the Q1 FY27 revenue run rate, targeting 25-30% growth. The Glymes business, while continuing to operate at a decent scale for the pharma industry, saw plans for capacity expansion withheld due to aggressive pricing from Chinese suppliers. The company is also monitoring potential impacts from China's anti-involution policies, which could see the removal of VAT/subsidies for specialty chemicals from January next year, potentially benefiting Tatva Chintan.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls